Top Stem Cell Companies Supported by the Maryland Stem Cell Research Fund

Published on : Published by : Alex Keown

Since its inception, MSCRF has invested over $170 million in over 500 projects to accelerate stem cell research, commercialization, and cures. With a 2023 fiscal year budget of $20.5M, MSCRF offers six funding opportunities to scientists and companies in the areas of clinical trials, discovery, commercialization, validation, launch, and post-doctoral fellowships. The fund has supported the creation and growth of many stem cell companies since launching the Accelerating Cures initiative in 2017.

Moving To An Allogeneic RNA Cell Therapy Program With Cartesian Therapeutics Dr. Metin Kurtoglu

Published on : Published by : BioBuzz Media

Cartesian Therapeutics’ Dr. Metin Kurtoglu joins Cell & Gene: The Podcast to explain their autologous RNA cell therapies, Descartes-08 for Myasthenia Gravis and Descartes-11 for multiple myeloma. He also sheds light on Descartes-25, their allogeneic RNA cell therapy, and the reasons for the move to “off-the-shelf.” Hear why the future of RNA cell therapy is not confined to rare and fatal diseases and subscribe so you never miss an episode!

Cartesian, BD and REGENXBIO’s Ken Mills Take Home Top Honors at MTC’s Industry Awards Celebration

Published on : Published by : Chris Frew

The Maryland Tech Council, the largest technology and life science trade association in the state, announced the winners of its 2022 Industry Awards Thursday at the Bethesda North Marriott Hotel & Conference Center. The event, which honored companies, executives, students, and educators in 15 categories, marked the first in-person gathering for the Industry Awards Celebration since 2019. 

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma

Published on : Published by : BioBuzz Media

Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, today announced that it has dosed the first patient in a Phase 1/2a multicenter clinical study evaluating Descartes-25 in patients with multiple myeloma.  To the company’s knowledge, Descartes-25 is the first off-the-shelf RNA cell therapy to enter clinical trials for any cancer and marks the company’s fifth FDA Investigational New Drug (IND) allowance in five years.  Descartes-25 is produced at Cartesian’s wholly owned cGMP manufacturing facility with the company’s proprietary RNA Armory® cell manufacturing platform.  This platform now includes an internally developed, Part 1271-compliant Master Cell Bank of human umbilical cord Mesenchymal Stem Cells (MSC) that was used to engineer Descartes-25.

Meet Your 2021 BioBuzz Award Winners

Orange banner with photos of people, with text saying "2nd Annual BioBuzz Awards - Presenting Your Winners"
Published on : Published by : BioBuzz Media

Today, we are excited to announce the winners of our 2nd Annual BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.

2021 BioBuzz Awards Finalists

Published on : Published by : BioBuzz Media

We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.

Cartesian Therapeutics to double footprint, headcount in Gaithersburg

Published on : Published by : Chris Frew

Gaithersburg’s Cartesian Therapeutics Inc. is expanding its local footprint and initiating an aggressive hiring spree as the company bolsters its leadership team — and looks to get a cell therapy candidate through the clinic.
The biopharma, which already occupies about 4,500 square feet at 704 Quince Orchard Road, is taking over another 3,500 square feet adjacent to its existing space in the building, Dr. Murat Kalayoglu, president and CEO of Cartesian, told the Washington Business Journal.
The company declined to disclose the projected cost of the expansion, citing confidentiality reasons per its contract with Alexandria Real Estate Equities Inc. (NYSE: ARE), which in partnership with South Duvall — an affiliate of Rockville’s Scheer Partners — paid $6.9 million for the 80,000-square-foot office building in 2018. The building in the Gaithersburg biotech corridor is also home to a flurry of local players, including Novavax Inc. (NASDAQ: NVAX), miRecule Inc., VLP Therapeutics Inc. and others.

Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis

Published on : Published by : BioBuzz Media

Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced clinical data from the first cohort of an ongoing Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (gMG). Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA).

Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma

Published on : Published by : BioBuzz Media

Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma Cartesian Therapeutics, a biopharmaceutical company that specializes in mRNA-engineered cell therapy, recently announced [….]

BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies

Published on : Published by : Alex Keown

Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum.